IBT Insider Trading

Insider Ownership Percentage: 4.74%
Insider Buying (Last 12 Months): £23,820
Insider Selling (Last 12 Months): GBX 0

International Biotechnology Insider Trading History Chart

This chart shows the insider buying and selling history at International Biotechnology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

International Biotechnology Share Price & Price History

Current Price: GBX 656
Price Change: Price Increase of +2 (0.31%)
As of 03/28/2024 05:35 PM ET

This chart shows the closing price history over time for IBT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

International Biotechnology Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/7/2023Caroline GulliverInsiderBuy2,500GBX 573£14,325
8/3/2023Katherine Cornish-BowdenInsiderBuy1,500GBX 633£9,495
5/11/2022Patrick MaxwellInsiderBuy3,725GBX 589£21,940.25
4/1/2022Patrick MageeInsiderBuy2,500GBX 633£15,825
3/21/2022Katherine Cornish-BowdenInsiderBuy1,500GBX 644£9,660
1/12/2022Katherine Cornish-BowdenInsiderBuy1,500GBX 684£10,260
11/2/2021Patrick MageeInsiderBuy4,000GBX 735£29,400
8/5/2021Caroline GulliverInsiderBuy2,000GBX 724£14,480
See Full Table

SEC Filings (Institutional Ownership Changes) for International Biotechnology (LON:IBT)

52.11% of International Biotechnology stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

International Biotechnology logo
International Biotechnology Trust plc specializes in investments in development stage and late stage companies. The majority of the fund's assets are generally invested in smaller and mid-capitalization quoted companies, with a minority in larger capitalization quoted companies. It makes long only investments. It prefers to invest in quoted or unquoted biotechnology and life sciences companies focused on drug discovery and development and in related sectors such as microbiology, life sciences, pharmaceutical research and development, gene research and development, medical devices or healthcare services. The fund seeks to invest in companies engaged in development and/or commercialization of a product, device or enabling technology and also invests in the therapeutic sub-sector. The fund also prefers to invest in companies with strong growth potential from the development and/or commercialization of either a biotechnology drug candidate, medical device or other enabling technology for medical research. It may also invest in specialty pharmaceuticals and life science tools. These companies can range from small private companies with strong science and people that need development funding, to large, multi-billion dollar biotechnology and medical device companies which have portfolios of products, many of which are already used in hospitals, clinics and pharmacies around the world. It makes majority of its investments in smaller and mid-capitalization quoted companies and seeks to invest up to thirty percent of the Company's assets in unquoted companies, while allowing an exposure of up to forty percent in unquoted companies (at the time of investment and after allowing for valuation write-ups and further follow-on investments). The fund typically invests in the United States, but seeks the best investments worldwide and so may also invest in Western Europe, Australia, and Asia. It typically invests between $1 million and $4 million in its portfolio companies. It exits its unquoted investments through the sale of these companies to strategic buyers including major pharmaceutical companies or, in some cases, and through a flotation.
Read More on International Biotechnology

Today's Range

Now: GBX 656
Low: 646
High: 660

50 Day Range

MA: GBX 660.81
Low: 630
High: 694

52 Week Range

Now: GBX 656
Low: 548
High: 704

Volume

50,026 shs

Average Volume

58,281 shs

Market Capitalization

£256.76 million

P/E Ratio

624.76

Dividend Yield

5.18%

Beta

0.18

Who are the company insiders with the largest holdings of International Biotechnology?

International Biotechnology's top insider shareholders include:
  1. Caroline Gulliver (Insider)
  2. Katherine Cornish-Bowden (Insider)
  3. Patrick Magee (Insider)
  4. Patrick Maxwell (Insider)
Learn More about top insider investors at International Biotechnology.